Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Provectus Pharma (PVCT)

Provectus Pharma (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Nevada, Las Vegas to Investigate Small Molecule Immunotherapy Rose Bengal for Tissue Regeneration and Repair Globe Newswire - Tue Jul 19, 2022

KNOXVILLE, TN, July 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program...

OTC.VN : 0.325 (+3.17%)
PVCT : 0.1931 (+0.94%)
Provectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress Globe Newswire - Thu Jun 30, 2022

KNOXVILLE, TN, June 30, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated data from the Company’s initial expansion cohort of...

OTC.VN : 0.325 (+3.17%)
PVCT : 0.1931 (+0.94%)
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio Globe Newswire - Thu Jun 23, 2022

KNOXVILLE, TN, June 23, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s shareholders have approved the proposals of...

OTC.VN : 0.325 (+3.17%)
PVCT : 0.1931 (+0.94%)
Provectus Biopharmaceuticals Presents Multiple Metabolic Complete Responders from PV-10® Treatment of Early-Stage Metastatic Uveal Melanoma Patients at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire - Wed Jun 8, 2022

29% of M1a patients achieved metabolic complete response (mCR)mCR patients alive up to >4 years after start of PV-10 treatmentPET tumor response...

OTC.VN : 0.325 (+3.17%)
PVCT : 0.1931 (+0.94%)
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of PH-10 Immuno-Dermatology Agent for Treatment of Inflammatory Dermatoses and Epithelial Diseases Globe Newswire - Tue May 3, 2022

KNOXVILLE, TN, May 03, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has...

PVCT : 0.1931 (+0.94%)
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Globe Newswire - Wed Apr 27, 2022

KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational...

PVCT : 0.1931 (+0.94%)
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology Globe Newswire - Tue Apr 26, 2022

KNOXVILLE, TN, April 26, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has...

PVCT : 0.1931 (+0.94%)
Provectus Biopharmaceuticals Seeks Stockholder Approval at 2022 Annual Meeting for Authority to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio Globe Newswire - Tue Apr 19, 2022

KNOXVILLE, TN, April 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that, in conjunction with the filing of the Company’s...

PVCT : 0.1931 (+0.94%)
Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board Globe Newswire - Thu Apr 14, 2022

KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Company’s...

PVCT : 0.1931 (+0.94%)
Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting Globe Newswire - Mon Apr 11, 2022

KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of...

PVCT : 0.1931 (+0.94%)

Barchart Exclusives

2 Small-Cap Stocks With 40% to 60% Upside Barchart - Sat May 4, 2:45PM CDT
Wall Street believes these two growth stocks will soar, driven by the demand for their products. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot